Role of Metallic Nanoparticles in Vaccinology: Implications for Infectious Disease Vaccine Development

Neto, Lázaro Moreira Marques; Kipnis, André; Junqueira-Kipnis, Ana Paula

doi:10.3389/fimmu.2017.00239

Cited by 96 publications

(56 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nonetheless, consistent with previous reports published from our group using MCP‐1 targeting peptides, zeta potential of MCG PAMs were within the threshold to be considered physiologically neutral, or within −10 and +10 mV, for prolonged circulation in vivo . Similar to MCG PAMs, SCG PAMs were 13.2 ± 2.2 nm in diameter with a polydispersity index of 0.23 ± 0.01 and zeta potential of 5.3 ± 2.6 mV (Figure S2, Supporting Information) …”

Section: Resultssupporting

confidence: 89%

Collagenase‐Cleavable Peptide Amphiphile Micelles as a Novel Theranostic Strategy in Atherosclerosis

Chin

Poon

Trac

et al. 2020

Advanced Therapeutics

View full text Add to dashboard Cite

Atherosclerosis is an inflammatory disease characterized by plaques that can cause sudden myocardial infarction upon rupture. Such rupture‐prone plaques have thin fibrous caps due to collagenase degradation, and a noninvasive diagnostic tool and targeted therapy that can identify and treat vulnerable plaques and may inhibit the onset of acute cardiac events. Toward this goal, monocyte‐binding, collagenase‐inhibiting, and gadolinium‐modified peptide amphiphile micelles (MCG PAMs) are developed. Monocyte chemoattractant protein‐1 (MCP‐1) binds to C‐C chemokine receptor‐2 expressed on pathological cell types present within plaques. Through the peptide binding motif of MCP‐1, MCG PAMs bind to monocytes and vascular smooth muscle cells in vitro. Moreover, using magnetic resonance imaging, MCG PAMs show enhanced targeting and successful detection of plaques in diseased mice in vivo and act as contrast agents for molecular imaging. Through the collagenase‐cleaving peptide sequence of collagen [VPMS‐MRGG], MCG PAMs can compete for collagenases that degrade the fibrous cap of plaques, providing therapy. MCG PAM‐treated mice show increased fibrous cap thickness by 61% and 113% histologically compared to nontargeting micelle‐ or PBS‐treated mice (p = 0.0075 and 0.001, respectively). Overall, this novel multimodal nanoparticle offers new theranostic opportunities for noninvasive diagnosis and treatment of atherosclerotic plaques.

show abstract

Section: Resultssupporting

confidence: 89%

Collagenase‐Cleavable Peptide Amphiphile Micelles as a Novel Theranostic Strategy in Atherosclerosis

Chin

Poon

Trac

et al. 2020

Advanced Therapeutics

View full text Add to dashboard Cite

show abstract

“…In addition to the size, shape and charge of the particles, the material may also influence the interaction with the macrophages. The material from which a nanoparticle is made has a direct influence on the functions of the antigen-presenting cells (Marques et al 2017). Gold nanoparticles are one of the most studied in vaccinology (see Marques et al 2017 for summary), but other metals such as iron oxide and nickel have also been investigated.…”

Section: Discussionmentioning

confidence: 99%

Macrophage-like THP-1 cells show effective uptake of silica nanoparticles carrying inactivated diphtheria toxoid for vaccination

2020

View full text Add to dashboard Cite

Nanoparticles may be used in vaccinology as an antigen delivery and/or an immunostimulant to enhance immunity. Porous silica has been identified as an effective adjuvant for more than a decade, and we have therefore investigated the take up rate by an immortalized macrophage-like cell line of a number of mesoporous silica nanoparticles (MSNPs) with differing diameter and pore size. The MSNPs were synthesized using a sol-gel reaction and post-synthesis removal of the template. The MSNPs showed a clear distribution in take up rate peaking at 217 nm, whereas a comparison with solid spherical nanoparticles showed a similar distribution peaking at 377 nm. The MSNPs were investigated before and after loading with antigen. Diphtheria toxoid was used as a proof-of-concept antigen and showed a peak macrophage internalization of 53.42% for loaded LP3 particles which had a diameter of 217.75 ± 5.44 nm and large 16.5 nm pores. Optimal MSNP sizes appeared to be in the 200-400 nm range, and larger pores showed better antigen loading. The mesoporous silica particles were shown to be generally biocompatible, and cell viability was not altered by the loading of particles with or without antigen.

show abstract

“…A wide range of molecules, including adjuvants and antigens can be conjugated on AuNPs at high density, resulting in improved immunogenicity and antigen presentation (157,158). AuNPs can be formulated for intranasal administration and can diffuse into the lymph nodes, triggering robust antigenspecific cytotoxic T-cell immune responses (159,160). Tao and coworkers have demonstrated that the peptide consensus M2e of influenza A viruses with a non-native cysteine residue at the C-terminal end could be attached on the AuNPs via thiolate-Au chemistry.…”

Section: Inorganic Nanoparticlesmentioning

confidence: 99%

Nanoparticle-Based Vaccines Against Respiratory Viruses

et al. 2019

View full text Add to dashboard Cite

The respiratory mucosa is the primary portal of entry for numerous viruses such as the respiratory syncytial virus, the influenza virus and the parainfluenza virus. These pathogens initially infect the upper respiratory tract and then reach the lower respiratory tract, leading to diseases. Vaccination is an affordable way to control the pathogenicity of viruses and constitutes the strategy of choice to fight against infections, including those leading to pulmonary diseases. Conventional vaccines based on live-attenuated pathogens present a risk of reversion to pathogenic virulence while inactivated pathogen vaccines often lead to a weak immune response. Subunit vaccines were developed to overcome these issues. However, these vaccines may suffer from a limited immunogenicity and, in most cases, the protection induced is only partial. A new generation of vaccines based on nanoparticles has shown great potential to address most of the limitations of conventional and subunit vaccines. This is due to recent advances in chemical and biological engineering, which allow the design of nanoparticles with a precise control over the size, shape, functionality and surface properties, leading to enhanced antigen presentation and strong immunogenicity. This short review provides an overview of the advantages associated with the use of nanoparticles as vaccine delivery platforms to immunize against respiratory viruses and highlights relevant examples demonstrating their potential as safe, effective and affordable vaccines.

show abstract

Role of Metallic Nanoparticles in Vaccinology: Implications for Infectious Disease Vaccine Development

Cited by 96 publications

References 70 publications

Collagenase‐Cleavable Peptide Amphiphile Micelles as a Novel Theranostic Strategy in Atherosclerosis

Collagenase‐Cleavable Peptide Amphiphile Micelles as a Novel Theranostic Strategy in Atherosclerosis

Macrophage-like THP-1 cells show effective uptake of silica nanoparticles carrying inactivated diphtheria toxoid for vaccination

Nanoparticle-Based Vaccines Against Respiratory Viruses

Contact Info

Product

Resources

About